Sign In
Buy CDXS
$1.40
-0.0800 (-5.41%)
At Close: Jul 31, 2026
Read This Before Selling Codexis, Inc. (NASDAQ:CDXS) Shares
11:49am, Monday, 24'th Feb 2020
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Codexis, Inc. (NASDAQ:CDXS) Shares Bought by California Public Employees Retirement System
09:54am, Sunday, 23'rd Feb 2020
California Public Employees Retirement System grew its holdings in shares of Codexis, Inc. (NASDAQ:CDXS) by 14.7% in the 4th quarter, according to its most recent disclosure with the Securities and Ex
Codexis to Hold 2019 Fourth Quarter and Full Year Conference Call on February 27
12:00pm, Thursday, 20'th Feb 2020
REDWOOD CITY, Calif., Feb. 20, 2020 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report 2019 fourth quarter and full year.
Codexis to Hold —…–9 Fourth Quarter and Full Year Conference Call on February —7
12:00am, Thursday, 20'th Feb 2020Weekly Research Analysts' Ratings Updates for Codexis (CDXS)
06:02pm, Monday, 17'th Feb 2020
Codexis (NASDAQ: CDXS) recently received a number of ratings updates from brokerages and research firms: 2/13/2020 – Codexis was downgraded by analysts at BidaskClub from a “sell” rating to a �
The "Synthetic Biology Market by Tools (Oligonucleotides, Enzymes, Synthetic Cells), by Technology (Gene Synthesis, Bioinformatics), by Application (Tissue Regeneration, Biofuel, Renewable Energy, Foo
$19.8B Synthetic Biology Market by Tools, Technology, Application and Region - Forecast to 2025
11:23am, Monday, 17'th Feb 2020
Dublin, Feb. 17, 2020 -- The "Synthetic Biology Market by Tools (Oligonucleotides, Enzymes, Synthetic Cells), by Technology (Gene Synthesis, Bioinformatics), by Application.
Brokerages Expect Codexis, Inc. (NASDAQ:CDXS) Will Announce Quarterly Sales of $21.05 Million
01:38am, Monday, 17'th Feb 2020
Equities research analysts predict that Codexis, Inc. (NASDAQ:CDXS) will post $21.05 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimate
Garrison Bradford & Associates Inc Buys The Carlyle Group Inc, Brookfield Asset Management ...
12:00am, Monday, 10'th Feb 2020Can You Imagine How Elated Codexis’s (NASDAQ:CDXS) Shareholders Feel About Its 386% Share Price Gain?
10:38am, Thursday, 06'th Feb 2020
We think all investors should try to buy and hold high quality multi-year winners. And we've seen some truly amazing...
ARK Investment Management LLC Grows Stock Position in Codexis, Inc. (NASDAQ:CDXS)
11:42am, Monday, 03'rd Feb 2020
ARK Investment Management LLC increased its holdings in Codexis, Inc. (NASDAQ:CDXS) by 8.5% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 683,855 shares of the
Have Insiders Been Buying Codexis, Inc. (NASDAQ:CDXS) Shares This Year?
12:52pm, Friday, 31'st Jan 2020
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Codexis (NASDAQ:CDXS) Lifted to Strong-Buy at ValuEngine
07:28am, Friday, 31'st Jan 2020
Codexis (NASDAQ:CDXS) was upgraded by equities researchers at ValuEngine from a “buy” rating to a “strong-buy” rating in a report issued on Friday, ValuEngine reports. CDXS has been the subjec
Codexis (NASDAQ:CDXS) Rating Lowered to Sell at BidaskClub
07:28am, Friday, 31'st Jan 2020
Codexis (NASDAQ:CDXS) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Friday, BidAskClub reports. Several other equities analysts h
Rubius launches early-stage study of lead drug in PKU
05:30pm, Thursday, 30'th Jan 2020
Dosing is underway in a Phase 1 clinical trial evaluating Rubius Therapeutics' (RUBY -4.5%) lead candidate RTX-134, an allogeneic off-the-shelf cell therapy, for the potential treatment of phenylketon
